top line line expect top line expect
top line line bottom line miss expect
revenu drop net loss yoy due
increas increas sg expens
remain cash support routin oper quarter
top line expect remain stabl mn expect
sale three celgen drug remain stabl newli
ad sale in-hous develop tislelizumab
zanubrutinib btk in-licens eusa drug
compens loss mileston incom
catalyst includ zanubrutinib approv mcl
cll/sll well tislelizumab approv
uc snda
file squamou nsclc china top-lin result trial
tislelizumab non-squam nsclc also expect
maintain outperform cut target price
increas revenu
reflect better visibl tislelizumab sale nsclc also
increas net loss mn factor
top line line bottom line miss expect
revenu drop yoy mn driven
yoy increas sale celgen drug china
drop mileston revenu due termin tislelizumab
inhibitor collabor celgen revenu reach
mn line expect net loss yoy
mn due increas increas
sg expens sharp increas sg cost due
increas headcount especi commerci team net loss
higher expect due ramp sg cost
remain cash bn includ bn amgen
support compani routin oper quarter
current quarterli cash burn rate mn
figur result summari
top line expect remain stabl expect top line
remain mn sale three celgen drug
slightli increas mn increas revlimid
vidaza off-set decreas abraxan per estim
in-hous develop tislelizumab zanubrutinib btk
inhibitor contribut mn revenu
number share mn
chg prev ep
estimate pot chg tp
drug obtain approv
in-licens eusa drug would small less
mn launch view
overal newli ad revenu sourc could compens
mn loss mileston revenu
catalyst zanubrutinib expect drug obtain
approv china relapsed/refractori r/r mantl cell lymphoma
mcl r/r chronic/smal
lymphocyt lymphoma cll/sll
file supplement new drug applic snda
zanubrutinib waldenstrm macroglobulinemia wm
tislelizumab expect
china
urotheli carcinoma uc file snda first-lin
treatment patient squamou nsclc china
addit top-lin result on-going trial tislelizumab
first-lin treatment non-squam nsclc china
announc addit expect blinatumomab product
recent beigene-amgen deal receiv approv china
maintain outperform cut tp increas
revenu mn reflect better visibl
tislelizumab sale nsclc also increas net loss
mn cut tp
h-share factor higher-
than-expect sg cost reiter outperform rate
due beigen strong portfolio recent drug approv near-term
catalyst tp base dcf model assum wacc
perpetu growth
tp
statu non-u analyst us disclosur credit suiss seek busi compani cover research report result investor
awar firm may conflict interest could affect object report investor consid report singl factor make invest
charl martineau pm univers toronto compani mention price
serena shao fei zheng jason liu certifi respect compani secur individu analyz view
express report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
price rate histori inc amgn oq
signifi initi assumpt coverag
effect juli nc denot termin coverag
price rate histori beigen bgne oq
signifi initi assumpt coverag
charl martineau pm univers toronto price rate histori beigen
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst
coverag univers consist compani cover analyst within relev sector outperform repres
attract neutral less attract underperform least attract invest opportun octob
canadian well european exclud turkey rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres attract neutral less
attract underperform least attract invest opportun latin america turkey asia exclud japan australia
stock rate base stock total return rel averag total return relev countri region benchmark india
bse sensex index prior octob canadian rate base stock absolut total return potenti
current share price rel attract stock total return potenti within analyst coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk
prior may rang outperform under-perform rate overlap neutral threshold
oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover multipl sector
credit suiss distribut stock rate bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform
